
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated Advanced Pancreatic Cancer
The FDA has granted fast track designation to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for the treatment of adult patients with KRAS G12D–mutated locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), including both first-line …